AMGEN INC

Listed Company

AMGNCIK 0000318154NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$36.75B

Net Income

$7.71B

Total Assets

$90.59B

Equity

$8.66B

Shares Out

539.71M

Op. Cash Flow

$9.96B

AMGN$366.31+22.78% · past yearDBEQ Basic

Daily closing prices

Business

Amgen Inc. discovers, develops, manufactures and delivers innovative biologic and small-molecule medicines to treat serious diseases including oncology, cardiovascular, inflammation, bone health and other therapeutic areas. The company markets over 20 principal products globally, including Prolia, Repatha, Otezla, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, Nplate, TEZSPIRE, and KYPROLIS, with a robust pipeline of product candidates in Phase 1–3 development. Amgen operates in one reportable segment (human therapeutics) and distributes products primarily through pharmaceutical wholesalers in the United States and direct-to-healthcare-providers channels internationally across approximately 100 countries.

Summary from 10-K filed 2026-02-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	36,751	33,424	28,190	26,323	25,979
Cost of sales	12,037	12,858	8,451	6,406	6,454
Research and development	7,272	5,964	4,784	4,434	4,819
Selling, general and administrative	7,050	7,096	6,179	5,414	5,368
Other	1,312	248	879	503	194
Total operating expenses	27,671	26,166	20,293	16,757	18,340
Operating income	9,080	7,258	7,897	9,566	7,639
Interest expense, net	−2,755	−3,155	−2,875	−1,406	−1,197
Other income, net	2,651	506	2,833	−814	259
Total income before income taxes	8,976	4,609	7,855	—	—
Provision for income taxes	1,265	519	1,138	794	808
Net income	7,711	4,090	6,717	6,552	5,893
Basic (in usd per share)	14.33	7.62	12.56	12.18	10.34
Diluted (in usd per share)	14.23	7.56	12.49	12.11	10.28
Basic (in shares)	538	537	535	538	570
Diluted (in shares)	542	541	538	541	573

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	9,129	11,973	10,944	7,629	7,989
Trade receivables, net	9,570	6,782	7,268	5,563	4,895
Inventories	6,225	6,998	9,518	4,930	4,086
Other current assets	4,133	3,277	2,602	2,388	2,367
Total current assets	29,057	29,030	30,332	22,186	19,385
Property, plant and equipment, net	7,913	6,543	5,941	5,427	5,184
Intangible assets, net	22,276	27,699	32,641	16,080	15,182
Goodwill	18,680	18,637	18,629	15,529	14,890
Other noncurrent assets	12,660	9,930	9,611	5,899	6,524
Total assets	90,586	91,839	97,154	65,121	61,165
Accounts payable	2,367	1,908	1,590	1,572	1,366
Accrued liabilities	18,523	17,641	15,359	12,524	10,731
Current portion of long-term debt	4,599	3,550	1,443	1,591	87
Total current liabilities	25,489	23,099	18,392	15,687	12,184
Long-term debt	50,005	56,549	63,170	37,354	33,222
Long-term deferred tax liabilities	1,366	1,616	2,354	11	—
Long-term tax liabilities	2,690	2,349	4,680	5,757	6,594
Other noncurrent liabilities	2,378	2,349	2,326	2,651	2,465
Contingencies and commitments (see Note 20)	—	—	—	—	—
Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding538.8 shares in 2025 and 536.9 shares in 2024	34,023	33,533	33,070	32,514	32,096
Accumulated deficit	−25,107	−27,590	−26,549	−28,622	−24,600
Accumulated other comprehensive loss	−258	−66	−289	−231	−796
Total stockholders equity	8,658	5,877	6,232	3,661	6,700
Total liabilities and stockholders equity	90,586	91,839	97,154	65,121	61,165

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation, amortization and other	5,167	5,592	4,071	3,417	3,398
Impairment of intangible assets	1,200	159	851	—	—
Stock-based compensation expense	494	530	431	401	341
Deferred income taxes	−721	−1,228	−1,273	−1,198	−453
(Gains) losses on equity securities	−2,064	159	−1,565	127	0
Other items, net	149	−177	−277	−303	−262
Trade receivables, net	−2,676	441	−1,015	−746	−429
Inventories	886	2,532	491	−742	−165
Other assets	−1,267	−652	−564	258	−237
Accounts payable	428	312	−402	154	−69
Accrued income taxes, net	−2,068	−1,011	−1,031	−647	−854
Long-term tax liabilities	311	−492	371	229	204
Accrued liabilities	499	92	953	97	—
Accrued sales incentives and allowance	2,065	1,194	935	846	404
Other liabilities	−156	−51	−222	−182	−48
Net cash provided by operating activities	9,958	11,490	8,471	9,721	9,261
Cash paid for acquisitions, net of cash acquired	−53	0	−26,989	−3,839	−2,529
Proceeds from sales of marketable securities	0	0	1,123	98	4,403
Proceeds from maturities of marketable securities	0	0	550	1,120	8,831
Purchases of property, plant and equipment	−1,858	−1,096	−1,112	−936	−880
Other	−32	50	224	100	−192
Net cash used in investing activities	−1,943	−1,046	−26,204	−6,044	733
Net proceeds from issuance of debt	0	0	27,777	6,919	4,945
Extinguishment of debt	−683	−659	−647	−297	0
Repayment of debt	−5,000	−3,600	−1,454	0	−4,150
Repurchases of common stock	0	−200	0	−6,360	−4,975
Dividends paid	−5,124	−4,832	−4,556	−4,196	−4,013
Other	−52	−124	−72	−103	−78
Net cash (used in) provided by financing activities	−10,859	−9,415	21,048	−4,037	−8,271
(Decrease) increase in cash and cash equivalents	−2,844	1,029	3,315	−360	1,723

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is AMGEN INC's CIK number?

AMGEN INC's SEC CIK number is 0000318154 (318154). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find AMGEN INC's SEC filings?

All of AMGEN INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did AMGEN INC last report earnings?

AMGEN INC (AMGN) most recently filed an earnings 8-K with the SEC on Apr 30, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000318154-26-000054). This is AMGEN INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is AMGEN INC's most recent earnings 8-K?

AMGEN INC's latest earnings 8-K (Item 2.02) was filed Apr 30, 2026 under accession 0000318154-26-000054. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View AMGEN INC's latest earnings 8-K →
Look up any company's CIK number →